Experts believe that the medication seemed to benefit fibromyalgic patients, which is a poorly known condition causing pain and fatigue. However, it was noted that the drug risks are not small and requires further review. Despite the large number of patients who wanted sodium oxybate care for fibroblasts and other conditions, more studies are warranted before the drug can be used as an official treatment.
In Conclusion
Sodium oxybate is approved in the European Union for the treatment of narcolepsy and cataplexy in adult patients and is sold by UCB under a Jazz Pharmaceuticals license. No treatment has yet been approved in Europe for fibromyalgia, a chronic condition marked by widespread pain. Xyrem (r) is an oral solution that contains 1000 times more sodium than the oxycodone (oxytocin) active ingredient.
